OrbitonOpen research workspace →
Novo Nordisk A/S logo

Novo Nordisk A/S

TSX:NOVOLive AI agent

Novo Nordisk is a global healthcare company with a rich history of over 100 years, founded by Marie and August Krogh, who were pioneers in diabetes treatment.

Investor website: https://novonordisk.com/

About

Novo Nordisk is a global healthcare company with a rich history of over 100 years, founded by Marie and August Krogh, who were pioneers in diabetes treatment. The company is dedicated to driving change for long-term health through innovative protein-based treatments for chronic diseases, particularly diabetes. Novo Nordisk's commitment to patient care and innovation has established it as a leader in the pharmaceutical industry.

Verified company data

Shares outstanding
4,443.5 million
Fully diluted shares
4,446.8 million
Projects
["Novo Nordisk Research Centre Oxford (NN R&D UK) is an innovative target discovery unit with a focus on identifying novel, game-changing therapies for patients with type 2 diabetes and cardiometabolic diseases. We employ advanced computational biology, state-of-the-art discovery screening technologies, genetics and human-centric cell systems to dissect pathophysiology and identify novel drug targets. The site is a fusion of the best of academia, biotech and big pharma in order to realize cutting-edge biology and start a target’s journey from bench to bedside. NN R&D UK operates at the boundaries of frontier science with a mandate to find dynamic, agile and distinctive new ways of working to diversify the company’s pipeline with disruptive medicines. Oxford Research Centre, Innovation Building, Old Road Campus, University of Oxford."]
Leadership
Maziar Mike Doustdar (CEO), Thilde Hummel Bøgebjerg (Executive Vice President, Enterprise IT & Quality), Hong Chow (Executive Vice President, Product & Portfolio Strategy, joined Novo Nordisk in February 2026, previously held leadership roles at Merck KGaA and Roche), Karsten Munk Knudsen (Executive Vice President, Chief Financial Officer (CFO), joined Novo Nordisk in 1999, has held various finance positions), Martin Holst Lange (Executive Vice President, R&D and Chief Scientific Officer (CSO)), Emil Kongshøj Larsen (Executive Vice President, International Operations), Jamey Millar (Executive Vice President, US Operations), Tania Sabroe (Executive Vice President, People, Organisation & Corporate Affairs), Kasper Bødker Mejlvang (Executive Vice President, Global Manufacturing & Supply), Elin Jäger (Senior vice president, Chief of Staff to CEO; Corporate Strategy & Sustainability), John F. Kuckelman (Senior vice president, Group General Counsel, Global Legal, IP and Security)

Verified data last updated:

Recent filings